Liquid biopsies have become a useful tool in precision medicine for therapy selection and have immense potential as a monitoring tool for the emergence of therapy resistance.
Canexia Health collaborated with Exactis Innovation on a study to monitor plasma ctDNA in metastatic colorectal cancer patients using Canexia Health’s Follow It assay detecting changes in key mutations and disease progression.
Speaker:
Melissa McConechy
Senior Manager, Assay Development - Canexia Health